Radiopharm Theranostics (ASX:RAD) partnered with Nasdaq-listed Lantheus to develop oncology radiopharmaceuticals in Australia, according to a Monday filing with the Australian bourse.
The partnership will see the company lead clinical development efforts, with Lantheus covering costs associated with the program, the filing said.
The company will receive up to $2 million in milestone payments for achieving key clinical development objectives, such as ethics committee approval, first patient dosing, and patient enrollment for the first imaging trial, according to the filing.
Radiopharm Theranostics shares rose nearly 9% in morning trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。